Airways Disease Section, National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, Dovehouse Street, London, SW3 6LY, UK.
Department of Medical Pharmacology, CHU and University of Bordeaux, Bordeaux, France.
Clin Pharmacokinet. 2017 Oct;56(10):1139-1154. doi: 10.1007/s40262-017-0524-6.
In recent years, pathways for the development and approval of bioequivalent inhaled products have been established for regulated markets, including the European Union (EU), and a number of orally inhaled products (OIPs) have been approved in the EU solely on the basis of in vitro and pharmacokinetic data. This review describes how these development pathways are structured and their implications for the treatment of airway diseases such as asthma. The EU guidance follows a stepwise approach that includes in vitro criteria as the first step. If all in vitro criteria are not met, the second step is based on pharmacokinetic evaluations, which include assessments of lung and systemic bioavailability. If all pharmacokinetic criteria are not met, the third step is based on clinical endpoint studies. In this review, the scientific rationale of the European Medicines Agency guidance for the development of bioequivalent OIPs is reviewed with the focus on the development of bioequivalent OIPs in the EU. Indeed, we discuss the advantages and disadvantages of the weight-of-evidence and stepwise approaches. The evidence indicates that the EU guidance is robust and, unlike clinical endpoint studies, the pharmacokinetic studies are far more sensitive to measure the minor differences, i.e. deposition and absorption rates, in drug delivery from the test and reference products and, thus, should be best suited for assessing bioequivalence. The acceptance range of the 90% confidence intervals for pharmacokinetic bioequivalence (i.e. 80-125% for both the area under the plasma concentration-time curve and maximum plasma concentration) represent appropriately conservative margins for ensuring equivalent safety and efficacy of the test and reference products.
近年来,已为监管市场(包括欧盟)建立了开发和批准生物等效吸入产品的途径,并且仅基于体外和药代动力学数据,在欧盟批准了许多吸入式药品。本文描述了这些开发途径的结构及其对治疗气道疾病(如哮喘)的影响。欧盟的指导遵循逐步方法,首先包括体外标准。如果未达到所有体外标准,则第二步基于药代动力学评估,其中包括对肺部和全身生物利用度的评估。如果未达到所有药代动力学标准,则第三步基于临床终点研究。在本文中,重点讨论了欧盟开发生物等效 OIP 的欧洲药品管理局指南的科学原理,并探讨了开发生物等效 OIP 的优缺点。实际上,我们讨论了证据权重法和逐步法的优缺点。有证据表明,欧盟的指导原则是可靠的,与临床终点研究不同,药代动力学研究更能灵敏地测量药物从测试和参考产品中的传递的微小差异,即沉积和吸收速度,因此,应该最适合评估生物等效性。药代动力学生物等效性(即血浆浓度-时间曲线下面积和最大血浆浓度的 90%置信区间为 80-125%)的接受范围代表了确保测试和参考产品的安全性和疗效等效的适当保守范围。